Blair William & Co. IL Has $4.56 Million Stock Position in Cardiff Oncology, Inc. $CRDF

Blair William & Co. IL reduced its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 12.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,213,606 shares of the company’s stock after selling 310,512 shares during the period. Blair William & Co. IL owned about 3.29% of Cardiff Oncology worth $4,560,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its stake in Cardiff Oncology by 23.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock valued at $69,000 after buying an additional 4,232 shares during the period. Invesco Ltd. raised its holdings in Cardiff Oncology by 24.9% during the second quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock valued at $75,000 after buying an additional 4,749 shares in the last quarter. AlphaCore Capital LLC raised its holdings in Cardiff Oncology by 8.2% during the third quarter. AlphaCore Capital LLC now owns 109,926 shares of the company’s stock valued at $226,000 after buying an additional 8,351 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Cardiff Oncology by 18.8% in the first quarter. Rhumbline Advisers now owns 63,142 shares of the company’s stock worth $198,000 after buying an additional 9,970 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Cardiff Oncology by 50.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock valued at $108,000 after purchasing an additional 11,497 shares during the last quarter. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on CRDF. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Piper Sandler cut their price target on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Wall Street Zen raised shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, March 4th. Finally, Noble Financial started coverage on shares of Cardiff Oncology in a report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.10.

Cardiff Oncology Stock Down 0.5%

NASDAQ:CRDF opened at $2.01 on Thursday. The firm has a market cap of $137.41 million, a PE ratio of -2.91 and a beta of 1.32. Cardiff Oncology, Inc. has a 12 month low of $1.48 and a 12 month high of $4.55. The company’s 50-day moving average price is $2.16 and its two-hundred day moving average price is $2.23.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%. On average, research analysts expect that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.